Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > ACADEMIA
ACADEMIA
- Kyoto Univ., Takeda Succeed in Treating Muscular Dystrophy in Model Mice Using Genome Editing
December 10, 2021
- With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects
December 9, 2021
- Swift Actions to Improve Diagnostic System, Control Costs Required to Prep for Potential Aducanumab Debut: JSDR Confab
November 30, 2021
- Anti-CGRP Antibodies Cut Headaches in 70% of Patients, but Cost Will Be Major Obstacle: Specialist
October 21, 2021
- Japan Headache Society Clarifies Patients Suitable for CGRP Migraine Meds, No Drug Selection Criteria Given for Now
October 21, 2021
- For Hypertension, Entresto Expected as or More Effective than ARBs/ACE Inhibitors: Professor
October 21, 2021
- NCC Kicks Off Asia’s Clinical Data Sharing Project, Starting with Bowel Cancer
October 4, 2021
- NCC to Launch Search Portal for Cancer Genomic Data on Oct. 4; Support Drug Makers’ R&D
October 1, 2021
- Forxiga Could Treat 3 Million CKD Patients in Japan, Potentially Be 1st Choice Drug: Professor
October 1, 2021
- Evrysdi Offers New Option for SMA Patients with Scoliosis: KOL
September 29, 2021
- Use Oral Dexamethasone for COVID-19 Patients Requiring Oxygen: Scientific Societies
September 10, 2021
- Oita University to Begin PI Study for Replicon RNA Vaccine in October
September 10, 2021
- Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
September 9, 2021
- Darzquro Expected to Treat 900 AL Amyloidosis Patients in Japan Annually: Specialist
September 6, 2021
- 1st COVID-19 Delta Variant Mutation Found in Japan: TMDU
August 31, 2021
- TMDU, Takeda Running Joint Research on Heteroduplex Oligonucleotide for Neuro Diseases
August 24, 2021
- Evrysdi Debut Expands SMA Treatment Options, Improved Use Expected for All 3 Drugs: Professor
August 16, 2021
- Osteoporosis Society Greatly Alarmed by Vitamin D3 Analog Shortages, Might Take Further Measures
July 29, 2021
- Scientific Societies Propose Measures for Osteoporosis Treatment amid Shortages of Vitamin D Analogs
July 21, 2021
- Japan KOL Pins Hopes on Pemazyre as 1st Biliary Tract Cancer Drug in 9 Years
July 16, 2021
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…